Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2009

01-03-2009 | Original Article

Clinical Significance of Interleukin-6 (Il-6) Gene Polymorphism and Il-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis

Authors: Renata Talar-Wojnarowska, Anita Gasiorowska, Beata Smolarz, Hanna Romanowicz-Makowska, Andrzej Kulig, Ewa Malecka-Panas

Published in: Digestive Diseases and Sciences | Issue 3/2009

Login to get access

Abstract

The aim of our study was to assess the clinical significance of -174G/C Il-6 gene polymorphism and Il-6 serum level in patients with pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP). The study included 41 with pancreatic adenocarcinoma, 56 with chronic pancreatitis, and 50 healthy volunteers, hospitalized between 2003 and 2006. Il-6 serum levels were measured with an enzyme-linked immunoassay and Il-6 gene polymorphism was studied in DNA isolated from peripheral blood. In PA and CP patients Il-6 serum levels were significantly higher than in the control group (P < 0.01). The levels of Il-6 in the patients with tumor size ≥3.5 cm were higher than that in patients with smaller tumors (P < 0.01). The elevated Il-6 levels were also correlated with the presence of liver metastases (P < 0.01). Mean Il-6 serum level was significantly higher in patients homozygous G/G for -174 Il-6 gene compared with patients with at least one C allele. Our findings indicate that -174G/C Il-6 gene polymorphism influences circulating Il-6 levels. Increased Il-6 serum levels may be correlated with tumor size and the presence of liver metastases in patients with pancreatic adenocarcinoma.
Literature
2.
go back to reference Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M et al (1992) Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 111:201–209PubMed Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M et al (1992) Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 111:201–209PubMed
3.
go back to reference Damas P, Ledoux D, Nys M, Wrindts Y, De Groote D, Franchimont P et al (1992) Cytokine serum level during severe sepsis in human Il-6 as a marker of severity. Ann Surg 215:356–362PubMedCrossRef Damas P, Ledoux D, Nys M, Wrindts Y, De Groote D, Franchimont P et al (1992) Cytokine serum level during severe sepsis in human Il-6 as a marker of severity. Ann Surg 215:356–362PubMedCrossRef
4.
go back to reference Fishman D, Faulds G, Jeffery R, Mohamed-Ali U, Yudkin JS, Humpherces S (1998) The effect of novel polymorphisms in the interleukine-6 gene on Il-6 transcription and plasma Il-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376. doi:10.1172/JCI2629 PubMedCrossRef Fishman D, Faulds G, Jeffery R, Mohamed-Ali U, Yudkin JS, Humpherces S (1998) The effect of novel polymorphisms in the interleukine-6 gene on Il-6 transcription and plasma Il-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376. doi:10.​1172/​JCI2629 PubMedCrossRef
5.
go back to reference Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard A et al (1994) Tumor necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 30:162–167. doi:10.1016/0959-8049(94)90079-5 CrossRef Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard A et al (1994) Tumor necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 30:162–167. doi:10.​1016/​0959-8049(94)90079-5 CrossRef
7.
go back to reference Wu CW, Wang SR, Chao MF, Wu TC (1996) Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91:1417–1422PubMed Wu CW, Wang SR, Chao MF, Wu TC (1996) Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91:1417–1422PubMed
8.
go back to reference Lai R, O’Brien S, Maushouri T, Rogers A, Kantarijan H, Keating M et al (2002) Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95:1071–1075. doi:10.1002/cncr.10772 PubMedCrossRef Lai R, O’Brien S, Maushouri T, Rogers A, Kantarijan H, Keating M et al (2002) Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95:1071–1075. doi:10.​1002/​cncr.​10772 PubMedCrossRef
9.
go back to reference Takeda K, Fujii N, Nitta Y, Sakihara H, Nakyama K, Rikishi H et al (1991) Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 82:1299–1308PubMed Takeda K, Fujii N, Nitta Y, Sakihara H, Nakyama K, Rikishi H et al (1991) Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 82:1299–1308PubMed
10.
go back to reference Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB (1989) Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135:427–433PubMed Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB (1989) Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135:427–433PubMed
11.
go back to reference DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M et al (2003) Interleukin-6174 G/C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051–8056PubMed DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M et al (2003) Interleukin-6174 G/C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051–8056PubMed
12.
go back to reference Nikiteas N, Tzanakis N, Gazouli M, Rallis G, Danilidis K, Theodoropoulus G et al (2005) Serum Il-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognosis implications. World J Gastroenterol 11:1639–1643PubMed Nikiteas N, Tzanakis N, Gazouli M, Rallis G, Danilidis K, Theodoropoulus G et al (2005) Serum Il-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognosis implications. World J Gastroenterol 11:1639–1643PubMed
13.
go back to reference Bowcock AM, Kidd JR, Lathrop GM, Daneshvar L, May L, Ray A et al (1988) The human “interferon-beta 2/hepatocyte stimulating factor/interleukin-6” gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 3:8–16. doi:10.1016/0888-7543(88)90152-8 PubMedCrossRef Bowcock AM, Kidd JR, Lathrop GM, Daneshvar L, May L, Ray A et al (1988) The human “interferon-beta 2/hepatocyte stimulating factor/interleukin-6” gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 3:8–16. doi:10.​1016/​0888-7543(88)90152-8 PubMedCrossRef
14.
go back to reference Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, Visvikis S et al (2005) Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and Il-6 concentrations: STANISLAS cohort. Eur J Hum Genet 13:109–117. doi:10.1038/sj.ejhg.5201294 PubMedCrossRef Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, Visvikis S et al (2005) Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and Il-6 concentrations: STANISLAS cohort. Eur J Hum Genet 13:109–117. doi:10.​1038/​sj.​ejhg.​5201294 PubMedCrossRef
15.
go back to reference Hefler LA, Crimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S et al (2003) An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 63:3066–3068PubMed Hefler LA, Crimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S et al (2003) An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 63:3066–3068PubMed
16.
go back to reference Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalrta R et al (2003) 174G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9:2173–2176PubMed Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalrta R et al (2003) 174G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9:2173–2176PubMed
18.
19.
go back to reference Sarner M, Cotton PB (1983) Classifications of pancreatitis. International Workshop, vol 25. King`s College, Cambridge, pp 756–759 Sarner M, Cotton PB (1983) Classifications of pancreatitis. International Workshop, vol 25. King`s College, Cambridge, pp 756–759
20.
go back to reference Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, Oca J et al (2003) Association of common polymorphisms in inflammatory genes interleukin (Il)-6, Il-8, tumor necrosis factor alpha, NFKB1 and peroxisome proliferator-activated receptor γ with colorectal cancer. Cancer Res 63:3560–3566PubMed Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, Oca J et al (2003) Association of common polymorphisms in inflammatory genes interleukin (Il)-6, Il-8, tumor necrosis factor alpha, NFKB1 and peroxisome proliferator-activated receptor γ with colorectal cancer. Cancer Res 63:3560–3566PubMed
23.
go back to reference Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Lizuka N et al (1996) Relationship between serum levels of interleukin 6, various diseases parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56:2776–2780PubMed Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Lizuka N et al (1996) Relationship between serum levels of interleukin 6, various diseases parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56:2776–2780PubMed
25.
go back to reference Kinoshita T, Ito H, Miki C (1999) Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85:2526–2531. doi:10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3 PubMedCrossRef Kinoshita T, Ito H, Miki C (1999) Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85:2526–2531. doi:10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3 PubMedCrossRef
26.
27.
go back to reference Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA (2002) Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 21:881–886PubMed Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA (2002) Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 21:881–886PubMed
28.
go back to reference Bhatnagar A, Wig JD, Majumdar S (2003) Immunological findings in acute and chronic pancreatitis. J Surg 73:59–64 Bhatnagar A, Wig JD, Majumdar S (2003) Immunological findings in acute and chronic pancreatitis. J Surg 73:59–64
29.
go back to reference Szuster-Ciesielska A, Daniluk J, Kandefer-Zerszen M (2000) Serum levels of cytokines in alcoholic liver cirrhosis and pancreatitis. Arch Immunol Ther Exp (Warsz) 48:301–307 Szuster-Ciesielska A, Daniluk J, Kandefer-Zerszen M (2000) Serum levels of cytokines in alcoholic liver cirrhosis and pancreatitis. Arch Immunol Ther Exp (Warsz) 48:301–307
30.
go back to reference Bomba T, Yoshioka U, Inoue H, Iwasaki Y, Hosoda S (1994) Serum levels of interleukin-1 beta and interleukin-6 in patients with chronic pancreatitis. J Gastroenterol 29:314–319. doi:10.1007/BF02358371 CrossRef Bomba T, Yoshioka U, Inoue H, Iwasaki Y, Hosoda S (1994) Serum levels of interleukin-1 beta and interleukin-6 in patients with chronic pancreatitis. J Gastroenterol 29:314–319. doi:10.​1007/​BF02358371 CrossRef
31.
go back to reference Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M et al (2001) A gender-dependent genetic predisposition to produce high levels of Il-6 is detrimental for longevity. Eur J Immunol 31:2357–2361. doi:10.1002/1521-4141(200108)31:8<2357::AID-IMMU2357>3.0.CO;2-XPubMedCrossRef Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M et al (2001) A gender-dependent genetic predisposition to produce high levels of Il-6 is detrimental for longevity. Eur J Immunol 31:2357–2361. doi:10.1002/1521-4141(200108)31:8<2357::AID-IMMU2357>3.0.CO;2-XPubMedCrossRef
33.
go back to reference Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA et al (2000) An Il-6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with immunodeficiency virus. Blood 96:2562–2567PubMed Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA et al (2000) An Il-6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with immunodeficiency virus. Blood 96:2562–2567PubMed
Metadata
Title
Clinical Significance of Interleukin-6 (Il-6) Gene Polymorphism and Il-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis
Authors
Renata Talar-Wojnarowska
Anita Gasiorowska
Beata Smolarz
Hanna Romanowicz-Makowska
Andrzej Kulig
Ewa Malecka-Panas
Publication date
01-03-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0390-z

Other articles of this Issue 3/2009

Digestive Diseases and Sciences 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.